Pulmatrix, Inc. (PULM)
| Market Cap | 87.24M |
| Revenue (ttm) | 12.32M |
| Net Income (ttm) | -20.45M |
| Shares Out | 33.92M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $1.67 |
| Previous Close | $1.68 |
| Change ($) | -0.02 |
| Change (%) | -0.89% |
| Day's Open | 1.65 |
| Day's Range | 1.61 - 1.72 |
| Day's Volume | 2,160,241 |
| 52-Week Range | 0.90 - 3.04 |
LEXINGTON, Mass., Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non...
LEXINGTON, Mass., Aug. 7, 2020 /PRNewswire/ -- Pulmatrix, Inc.
Pulmatrix (PULM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
LEXINGTON, Mass., June 26, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-...
January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.
Shares of Pulmatrix Inc. more than doubled Monday, rocketing 124% on heavy volume, after the company said it entered into a "binding term sheet" with Cipla Ltd.
About PULM
Pulmatrix, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease... [Read more...]
| Industry Biotechnology | Founded 2003 |
| CEO Teofilo Raad | Employees 22 |
| Stock Exchange NASDAQ | Ticker Symbol PULM |
Financial Performance
In 2019, Pulmatrix's revenue was $7.91 million, an increase of 5,069.93% compared to the previous year's $153,000. Losses were -$20.60 million, 0.16% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for Pulmatrix stock is "Buy" and the 12-month stock price forecast is 10.00.